Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botox for Forward Head Posture with Associated Episodic Headache
NCT01350375Phase 3Completed
- Sponsor
- The Research Center of Southern California
- Start
- Sep 2009
- Primary completion
- Jan 2013
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of botulinum toxin type A in forward head posture (FHP) (2 arms), sponsored by The Research Center of Southern California. Primary endpoints: Change in number of headache free days at 4 months, Percentage of days with headache at 4 months and 3 more. Started Sep 2009; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
forward head posture (FHP)
Beyond the preview
Go deeper on NCT01350375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01350375.